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Uric acid andblood pressure: exploring the role of
uric acid production inTheMaastricht Study
Lieke E.J.M. Scheepersa,b, Annelies Boonena,b, Pieter C. Dagnelieb,c,d, Miranda T. Schramc,e,f,
Carla J.H. van der Kallenc,e, Ronald M.A. Henryc,e,f, Abraham A. Kroonc,e,f, Coen D.A. Stehouwerc,e,
and Ilja C.W. Artsc,d,g
Objective: Accumulation of reactive oxygen species by
increased uric acid production has been suggested as a
possible underlying mechanism for the association
between uric acid and high blood pressure (BP). We,
therefore, investigated the association between serum uric
acid concentration and 24-h urinary uric acid excretion, as
proxy for uric acid production, with ambulatory 24-h blood
pressure and hypertension.
Methods: Cross-sectional analyses were conducted among
2555 individuals [52% men, mean age 60.08.2 years;
27% type 2 diabetes (by design)] from The Maastricht
Study. Multivariable regression analyses were performed to
investigate the association of serum uric acid and 24-h
urinary uric acid excretion with 24-h pulse pressure, 24-h
mean arterial pressure (MAP), and hypertension.
Results: After adjustment for traditional hypertension
risk factors, serum uric acid concentration (per SD of
81 mmol/l) was associated with higher 24-h MAP [b
0.63 mmHg; confidence interval (CI) 0.27–1.00] and
positively associated with hypertension (odds ratio 1.43;
CI 1.27–1.61). Urinary uric acid excretion (per SD of
140 mg/day/1.73 m2) was associated with higher 24-h MAP
(b 0.79 mmHg; CI 0.46–1.12) and with hypertension (odds
ratio 1.13; CI 1.02–1.25). There was no significant
association between serum and 24-h urinary uric acid
excretion with 24-h pulse pressure. There was no
interaction with sex or age for the aforementioned
associations.
Conclusion: Higher serum and urinary uric acid
concentrations were associated with higher 24-h MAP and
hypertension. These results suggest that serum and 24-
urinary uric acid concentrations, the latter as proxy for uric
acid production are, independent of each other, associated
with BP and hypertension.
Keywords: blood pressure, hypertension, mean arterial
pressure, pulse pressure, reactive oxygen species, uric acid,
xanthine dehydrogenase, xanthine oxidase, xanthine
oxidoreductase
Abbreviations: BP, blood pressure; CI, confidence
interval; eGFR, estimated glomerular filtration rate; MAP,
mean arterial pressure; OR, odds ratio; PP, pulse pressure;
RAAS, renin–angiotensin–aldosterone system; ROS,
reactive oxygen species; T2DM, type 2 diabetes mellitus;
UA, uric acid
INTRODUCTION
U
ric acid, the final product of purine catabolism, has
been associated with blood pressure (BP) and
hypertension. Recent meta-analyses showed a sig-
nificant association between serum uric acid and incident
hypertension, independent of traditional risk factors [1,2].
Several plausible mechanisms have been proposed
that causally link uric acid with elevated BP and hyperten-
sion. One mechanism includes the activation of the renin–
angiotensin–aldosterone system (RAAS) by elevated con-
centrations of uric acid, leading to increased production of
the vasoconstrictor angiotensin II [3]. Another possible
mechanism not directly related to uric acid concentration,
but rather to its production, is the generation of reactive
oxygen species (ROS) during the production of uric acid.
The enzyme xanthine oxidoreductase catalyzes the break-
down of hypoxanthine to xanthine and the latter to uric
acid. When oxygen is the electron acceptor, superoxide
radical anion (O2) [4] and hydrogen peroxide (H2O2) are
generated as by-products of the oxidation step. These ROS
directly reduce the bioavailability of the vasodilator nitric
oxide and lead to the formation of peroxynitrite, which can
increase endothelial nitric oxide synthase uncoupling
resulting in even more ROS formation [5,6].
Studies published so far have focused mostly on serum
uric acid and have ignored the distinction between uric acid
concentration and its production. As the production of uric
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acid may contribute, independent of uric acid concen-
tration, to the pathogenesis of hypertension, the production
should be investigated as well [7]. Facing the problem that it
is not possible to directly measure uric acid production in a
large population of individuals, and that uric acid concen-
tration is not an adequate marker for production, proxies
for uric acid production need to be investigated. Under
normal conditions, the body compensates for increased
uric acid production by increasing uric acid excretion, so
that serum uric acid remains stable and within the normal
range of 200–430 mmol/l for men and 120–340 mmol/l for
women [8]. Uric acid is predominantly excreted via the
urine; therefore, we used 24-h urinary uric acid excretion as
a proxy for uric acid production.
In view of the above, we aimed to evaluate whether
serum uric acid concentration and/or 24-h urinary uric acid
excretion, as proxy for uric acid production are, independ-
ent of each other, associated with 24-h ambulatory BP and
hypertension. We analysed the pulsatile and steady com-
ponent of BP captured by 24-h pulse pressure (PP) and 24-h
mean arterial pressure (MAP), respectively.
METHODS
Study population and design
We used data from The Maastricht Study, an observational
prospective cohort study. The rationale and methodology
have been described previously [9]. In brief, the study
focuses on the aetiology, pathophysiology, complications
and comorbidities of type 2 diabetes mellitus (T2DM) and is
characterized by an extensive phenotyping approach.
Eligible for participation were all individuals aged between
40 and 75 years and living in the southern part of The
Netherlands. Participants were recruited through mass
media campaigns and from municipal registries and the
regional Diabetes Patient Registry through mailings.
Recruitment was stratified according to known T2DM sta-
tus, with an oversampling of individuals with T2DM, for
reasons of efficiency. The present report includes cross-
sectional data from the first 3451 participants, who com-
pleted the baseline survey between November 2010 and
September 2013. The examinations of each participant
were performed within a time window of 3 months. The
study has been approved by the institutional medical
ethical committee (NL31329.068.10) and the Minister of
Health, Welfare and Sports of The Netherlands (Permit
131088-105234-PG). All participants gave written informed
consent.
For the present study, we excluded individuals without
data on serum uric acid (n¼ 4), creatinine (n¼ 6), 24-h
urine collection (n¼ 167), ambulatory BP (n¼ 482), level
of education (n¼ 77), smoking status (n¼ 63), alcohol
consumption (n¼ 69), BMI (n¼ 3), estimated glomerular
filtration rate (eGFR; n¼ 33), or diabetes duration
(n¼ 105). We also excluded individuals with type 1 dia-
betes mellitus (n¼ 40) or on uric acid lowering therapy (i.e.
allopurinol, benzbromarone; n¼ 67). A total of 2555 indi-
viduals were included in the present analyses (Fig. 1).
Twenty-four-hour ambulatory blood pressure
measurement
Ambulatory BP was measured with ambulatory 24-h BP
monitoring (WatchBP O3; Microlife AG, Widnau, Switzer-
land). Cuffs were applied to the participants’ nondominant
arm. Measurements were done every 15min during day-
time (0800–2300 h) and every 30min during the night
(2300–0800 h) for a total of 24 h. Mean 24-h BP measure-
ments were only calculated if there were more than 14 valid
measurements at daytime and less than seven valid
measurements at night, according to the recommendation
of the British Hypertension Society [10]. Mean 24-h SBP and
DBP were calculated based on hourly averages [11]. Twenty
four-hour mean PP was defined as 24-h SBP24-h DBP,
and MAP as mean 24-h DBPþ (0.412mean 24-h PP) [12].
Hypertension was defined as the use of antihypertensive
medication, mean 24-h SBP of at least 135 mmHg, or
mean 24-h DBP of at least 85mmHg [13]. Use of antihy-
pertensive medication was assessed during a medication
interview, where generic name, dose, and frequency were
registered.
Uric acid determination
After an overnight fast, venous blood samples were col-
lected to assess serum uric acid and creatinine concen-
trations with standard (enzymatic and/or colorimetric)
methods by an automatic analyzer [Beckman Synchron
LX20; Beckman Coulter Inc., Brea California, USA or the
Roche Cobase601 hs-cTnT assay (F Hoffmann-La Roche,
Basel, Switzerland) on the Cobas 6000 analyzer for the last
2585 samples] at Maastricht University Medical Centre (The
Netherlands).
To assess urinary uric acid and creatinine excretion,
participants were requested to collect a 24-h urine sample.
FIGURE 1 Flow-chart of study participants. eGFR, estimated glomerular filtration
rate.
Uric acid production and blood pressure
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Participants were instructed both orally and in writing on
the procedure concerning the 24-h urine collection. Only
urine collections with a collection time between 20 and
28-h were considered valid, in case of violation participants
were asked to collect urine once more. Urinary uric acid
and creatinine concentration were measured with a stand-
ard immunoturbidimetric assay by an automatic analyzer
(Beckman Synchron LX20; Beckman Coulter Inc.) and
multiplied by collection volume to obtain the 24-h urinary
uric acid excretion. According to the DuBois and DuBois
equation, 24-h urinary uric acid and creatinine excretion
were adjusted for body surface [14].
Covariates
To determine diabetes status, all participants (except those
who use insulin) underwent a standardized 2-h 75 g oral
glucose tolerance test after an overnight fast as previously
described [9]. Glucose metabolism was defined according
to the WHO 2006 criteria into normal glucose metabolism,
impaired fasting glucose, impaired glucose tolerance, and
T2DM [15]. For this study, we defined having either
impaired fasting glucose or impaired glucose tolerance
as prediabetes.
Weight and height were measured without shoes and
wearing light clothing using a scale and stadiometer to the
nearest 0.5 kg or 0.1 cm (Seca, Hamburg, Germany). BMI
was calculated as body weight (kg) divided by height
squared (m2). Waist and hip circumference were measured
in duplicate midway between the lower rib margin and the
iliac crest at the end of expiration and at the widest level
over the greater trochanters, respectively (Seca, Hamburg,
Germany). Waist-to-hip ratio was calculated as the mean of
two waist circumference measurements divided by the
mean of two hip circumference measurements. As pre-
viously described [9], diabetes duration, education level,
smoking status, and alcohol consumption were assessed by
means of a self-reported questionnaire. Level of education
was self-reported and classified into eight categories: no
education; primary education; lower vocational education;
intermediate general secondary education; intermediate
vocational education; higher general secondary education;
higher vocational education; and university. For this study,
three groups were created for educational level: low (levels
1–3), middle (levels 4–6), and high (levels 7 and 8).
Smoking status was based on self-report of smoking
cigarettes, cigars, and/or pipe tobacco and divided into
three categories, that is, nonsmoker, former smoker, and
current smoker. Alcohol consumption was self-reported as
the number of alcohol consumptions/week. One standard
alcohol consumption is equivalent to 10 g (or 13ml) alco-
hol. This corresponds to one glass of beer of 250 ml (5%
alcohol), one glass of wine of 100 ml (12% alcohol), or one
glass of spirit of 35ml (35% alcohol) [16]. For analyses, total
alcohol consumption was evaluated in grams of alcohol/
week. The patients were grouped into three categories, that
is, nonconsumers (0 g of alcohol/week), low consumers
(70 g of alcohol/week for females and 140 g of alcohol/
week for males), and high consumers (>70 g of alcohol/
week for females and >140 g of alcohol/week for males).
Physical activity was determined from the Community
Healthy Activities Model Program for Seniors (CHAMPS)
questionnaire (h/week). Activities accounted were walk-
ing, cycling, gardening, household work, jogging/running,
swimming, tennis, team sport, and exercise, regardless
whether the activity was on a light or intense. GFR was
estimated using the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) equation based on both serum
creatinine and serum cystatin C [17]. Use of uric acid low-
ering (allopurinol, febuxostat, probenecid, benzbromar-
one) and glucose-lowering medication were as well
assessed during the medication interview.
Statistical analysis
The characteristics of the participants are given as mean
values SD for continuous variables and as numbers and
proportions for categorical variables. To check if urinary
uric acid excretion is an independent marker and does
not represent serum uric acid concentration we created
a scatterplot and calculated the R2 between those two
variables.
Multiple linear or logistic regression analyses were used
to determine the association between the independent
variables serum uric acid concentration and 24-h urinary
uric acid excretion with the dependent variables ambulat-
ory 24-h PP, 24-h MAP, and the odds ratio (OR) of prevalent
hypertension. In the first model, the results of the crude
analyses were presented. In the second model, crude
results were adjusted for sex, age, glucose metabolism
status, smoking status, alcohol consumption, eGFR, level
of education, use of diabetes medication (no, oral medi-
cation, insulin with or without oral medication), RAAS
inhibitors and other antihypertensive medication (includ-
ing b-blockers) that have no known uricosuric properties,
losartan (known as a RAAS inhibitor with a uricosuric
effect) [18,19], and antihypertensive medication and lipid-
lowering medication that may have a uricosuric effect (i.e.
secondary uricosurics, amlodipine [20], atorvastatin [21],
rosuvastatin [21]). In the third model, the analyses with
serum uric acid were additionally adjusted for 24-h urinary
uric acid excretion; and the associations with 24-h urinary
uric acid excretion were additionally adjusted for serum
uric acid. To explore if serum and urinary uric acid con-
centrations are, independent of each other, associated with
BP and hypertension, the logistic regression models were
adjusted for the same covariates, except for the use of
antihypertensive medication, which is part of the definition
of the outcome.
As it has been suggested that uric acid has a more
pronounced effect in younger and female individuals, we
investigated whether the association between serum uric
acid concentration and urine uric acid excretion with
ambulatory BP and hypertension differed with sex and
age [22–25].
As an elevated uric acid may be a consequence of a high
BMI or waist-to-hip ratio, adjustment for BMI or waist-to-
hip ratio in the analyses may lead to overadjustment and
these variables were, therefore, not included in the main
analyses. In a sensitivity analysis, we additionally adjusted
for BMI or waist-to-hip ratio [26]. Owing to the large
number of missing values on physical activity (n¼ 278)
this variable was not included as potential confounder in
the main analyses. A sensitivity analysis was performed to
Scheepers et al.
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control for this variable in the subset of participants with
complete data.
The null hypothesis was rejected for a two-sided P value
was less than 0.05, except for the interaction analyses,
where a P value less than 0.10 was used. Analyses were
conducted using SPSS version 23 for windows (SPSS, Inc.,
Chicago, Illinois, USA).
RESULTS
The overall study population consisted of 2555 individuals
with an average age of 59.8 (SD 8.1) years, 51% of whom
were men. Owing to oversampling of individuals with dia-
betes 24% (n¼ 606) had T2DM. Table 1 shows the general
characteristics of the study population and the individuals
excluded from the analyses. On average the serum uric acid
concentration was 329 mmol/l (SD 81) and 24-h urinary uric
excretion was 518mg/min per 1.73m2 (SD 140). In total 1103
individuals (43%) had hypertension, of these 947 (86%) were
on antihypertensive medication. In the remaining 156
patients (14%), the diagnosis of hypertension relied on the
threshold being exceeded for SBP (n¼ 49; 31%), DBP
(n¼ 45; 29%), or both (n¼ 62; 40%). Individuals excluded
from analyses had a lower level of education, slightly higher
BMI, and were more often T2DM or hypertensive patients.
The variance in serum uric acid, while significant
(P value <0.001), explains only 0.9% of the variance in
urinary uric acid excretion (Fig. 2).
Serum uric acid and 24-h blood pressure
Crude linear regression analysis showed that a one SD
(81 mmol/l) higher serum uric acid concentration was
associated with 1.73 mmHg (CI, 1.44 to 2.02 mmHg) higher
TABLE 1. Characteristics of The Maastricht Study population and the individuals excluded from the analyses because of missing values
Study population (n¼2555) Missing
Excluded because of missing
values (n¼896)
Serum uric acid (mmol/l) 329.381.3 6 331.885.00
Serum creatinine (mmol/l) 77.216.1 4 77.417.7
Urine uric acid excretion (mg/day per 1.73 m2) 518.1139.92 127 507.5 181.6
Urine creatinine excretion (mmol/day per 1.73 m2) 12.02.8 78 11.94.1
Fractional uric acid excretion (FEUA) 9.3%5.3 173 9.5%10.4
Age (years) 59.88.1 0 59.68.6
Male sex (n) 51.0% (1303) 0 52.7% (472)
BMI (kg/m2) 26.84.3 5 27.95.1
Waist-to-hip ratio 0.940.09 4 0.96 (0.10)
Smoking status,(n) 63
Never 35.9% (916) 28.3% (254)
Past 52.2% (1333) 46.4% (416)
Current 12.0% (306) 18.2% (163)
Alcohol consumption, (n) 69
No 16.9% (432) 22.0% (197)
Low 56.6% (1446) 47.9% (429)
High 26.5% (677) 22.4% (201)
Educational level, (n) 77
Low 31.4% (801) 37.1% (332)
Medium 28.6% (731) 24.8% (222)
High 40.0% (1023) 29.6% (265)
Physical activity (hours/week)a 14.58.2 179 13.07.8
eGFR (ml/min per 1.73 m2) 88.2514.50 55 87.716.5
Glucose metabolism status, (n) 0
Normal glucose metabolism 60.6% (1549) 41.9% (375)
Impaired fasting glucose 4.3% (111) 3.6% (32)
Impaired glucose tolerance 11.3% (289) 8.8% (79)
Type 2 diabetes mellitus 23.7% (606) 41.2% (369)
Other type of diabetes n/a 4.5% (41)
Diabetes treatment among individuals with T2DM, (n) 4
No medication 25.1% (152) 15.5% (57)
Oral medication 55.0% (333) 58.7% (216)
Insulin with or without oral medication 20.0% (121) 25.8% (95)
Diabetes duration (years), median (range) 8.47.2 178 7.46.9
Hypertension (%) 43.2% (1103) 406 59.8% (293)
Use of antihypertensive medication, (n) 37.1% (947) 4 44.6% (353)
RAAS-inihibitors 24.7% (631) 34.3% (307)
Other antihypertensives, no uricosuric effect 20.6% (527) 30.7% (275)
Losartan 2.9 (75) 3.8% (34)
Secondary uricosuric 13.5% (346) 20.4% (182)
Mean arterial pressure 24-h (mmHg) 88.57.9 404 89.88.5
Pulse pressure 24-h (mmHg) 45.28.5 404 47.59.8
Data are presented as mean and SD unless otherwise indicated.
eGFR, estimated glomerular filtration rate; FEUA, fractional excretion of uric acid; RAAS, renin–angiotensin–aldosterone system; T2DM, type 2 diabetes mellitus.
aMissing data for 278 individuals on variable physical activity.
Uric acid production and blood pressure
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24-h MAP and greater odds for hypertension (OR 1.89; CI,
1.73–2.07; Table 2, model 1). Further adjustment for sex,
age, and glucose metabolism status, smoking status, alcohol
consumption, education, eGFR, duration of diabetes and
use of antihypertensive, or diabetes medication, did not
materially change the result (model 2). Furthermore, results
remained significant with additional adjustment for 24-h
urinary uric acid excretion (model 3). The association with
24-h PP was significant in the crude analysis (Table 2, model
1), but lost significance after adjustment for potential con-
founders (models 2 and 3).
Twenty-four-hour urine uric acid excretion and
twenty-four-hour blood pressure
Crude linear regression analysis showed that a one SD
higher 24-h urinary uric acid excretion (140 mg/day per
1.73 m2) was associated with higher 24-h MAP (b 1.98; CI,
1.69–2.28 mmHg) and greater odds for hypertension (OR
1.26; CI 1.16–1.36; Table 2, model 1). The associations of
serum uric acid with 24-h MAP and hypertension did not
materially change after further adjustment for potential
confounders (model 2). Further adjustment for serum uric
acid concentration did not materially changes the results
(model 3). The association between urinary uric acid
excretion and 24-h PP was significant in the crude analysis
(b 1.10; CI, 0.77–1.42 mmHg), but lost significance after
adjustment for potential confounders (Table 2, models
2 and 3; P value <0.15).
Effect modification by age or sex
To determine whether the associations between serum uric
acid and urine uric acid excretion with ambulatory PP, MAP,
and hypertension were different across sex and age strata,
an interaction term was added to the fully adjusted
regression models. No significant interaction with sex or
age was identified in any of the investigated associations
(P value >0.10).
Sensitivity analyses
Including BMI or waist-to-hip ratio as a covariate to model 3
did not materially alter the associations between serum uric
acid and BP or hypertension. However, the association
between urinary uric acid excretion and hypertension
was attenuated after including both BMI (OR 0.99;
P¼ 0.80) and waist-to-hip ratio (OR 1.04; P¼ 0.45).
Additional adjustment for physical activity did not mate-
rially alter the associations of serum uric acid and urinary
uric acid excretion with ambulatory PP, MAP, and hyper-
tension (data not shown).
DISCUSSION
The study represents a comprehensive analysis of the
association of uric acid with ambulatory BP and hyperten-
sion in middle-aged individuals. Serum uric acid concen-
tration and 24-h urinary uric acid excretion, as proxy for uric
acid production, were independent of each other associ-
ated with ambulatory MAP and hypertension. To the best
of our knowledge, this study is the first to show an
TABLE 2. Associations between serum uric acid and urinary uric acid excretion with ambulatory mean arterial pressure, pulse pressure and
hypertension
Mean arterial
pressure
Pulse
pressure Hypertensiona
b (95% CI) P value b (95% CI) P value Odds ratio (95% CI) P value
Serum uric acidb
Model 1 1.73 (1.44–2.03) <0.001 1.70 (1.37–2.02) <0.001 1.89 (1.73–2.07) <0.001
Model 2 0.70 (0.35–1.07) <0.001 0.09 (0.28–0.45) 0.65 1.45 (1.29–1.63) <0.001
Model 3 0.63 (0.27–1.00) <0.01 0.08 (0.30–0.43) 0.73 1.43 (1.27–1.61) <0.001
Uric acid excretionc
Model 1 1.98 (1.69–2.28) <0.001 1.10 (0.77–1.42) <0.001 1.26 (1.16–1.36) <0.001
Model 2 0.84 (0.51–1.16) <0.001 0.24 (0.08–0.57) 0.15 1.16 (1.04–1.28) <0.01
Model 3 0.79 (0.46–1.12) <0.001 0.24 (0.09–0.57) 0.15 1.13 (1.02–1.25) 0.03
Medication: in the adjusted analyses, no adjustment for antihypertensive medication.
Model 1: crude. Model 2 adjusted for age, sex, glucose metabolism status (normal, impaired, T2DM), smoking status (never, current, former), alcohol consumption (no, low, high),
education (low, middle, high), eGFR, use of diabetes medication (no, insulin with or without oral medication) and antihypertensive medication (no, RAAS inhibitors, diuretics or other b-
blockers and calcium), and duration of diabetes. Model 3, analyses with serum uric acid were additionally adjusted for 24-h urinary uric acid excretion; and the associations with 24-h
urinary uric acid excretion were additionally adjusted for serum uric acid.
CI, confidence interval.
aHypertension is defined as a 24-h SBP of more than 135, or DBP more than 85 or the use of antihypertensive
bSerum uric acid expressed/SD (81 mmol/l)
cUric acid excretion in 24-h urine expressed/SD (140 mg/day/1.73 m2).
FIGURE 2 Uric acid excretion in 24-h urine (mg/1.73 m2) as a function of serum
uric acid (mg/dl) in 2555 participants from The Maastricht Study.
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independent association of 24-h urinary uric acid excretion,
as proxy for uric acid production, with ambulatory BP
and hypertension.
Our results are in line with prior research showing that
serumuric acidwas associatedwithhypertension, independ-
entof traditionalhypertension risk factors [2]. Ameta-analysis
performed by Wang et al. in 2014 [2], showed that a 1mg/dl
increase in uric acid was associated with an increased risk
of incident hypertension (adjusted relative risk 1.15; CI,
1.06–1.26). In the current cross-sectional study, a similar
OR of 1.20 (CI, 1.10–1.31) for each 1mg/dl higher serum
uric acid concentration was found. In the present study, we
found no age or sex-related difference in the association
between serum uric acid and any of the outcomes. This is in
contrast with the meta-analysis performed by Grayson et al.
[1] which showed that the risk of hypertension among
individuals with hyperuricemia was significantly larger in
younger individuals and women. This contrasting finding
may be attributed to the inclusion criterium of an age of 40
years and older, resulting in a relative high age of our study
population (mean age of 60.0 years).
There are no earlier studies examining the association
between urinary uric acid excretion, as proxy for uric acid
production, and BP. We showed that urinary uric acid
excretion was significantly associated with ambulatory
MAP and hypertension, after adjustment for potential con-
founders including serum uric acid. These findings confirm
our hypothesis that increased uric acid production is associ-
ated with BP and hypertension. Uric acid is produced
during the metabolism of endogenous (DNA, RNA, and
ATP) and exogenous (dietary) purines. Previous studies
showed that an increase in uric acid production, either by
endogenous or exogenous supply, increases urinary uric
acid excretion [8]. Approximately, 70% of the produced uric
acid is eliminated by the kidney and 30% by the intestine
(extra-renal pathway), whether the relative contribution of
renal and extra-renal excretion is comparable in case of
increased uric acid production needs investigation [27]. In
case of decreased extra-renal excretion, serum uric acid and
urinary uric acid excretion will increase. Among white
individuals approximately 11% (Haplotype Mapping, Han
Chinese in Beijing, Japanese in Tokyo) has the Q141K
mutation in the urate transport ABCG2, which leads to a
decrease in extra-renal uric acid excretion, causing
increased serum and urinary uric acid concentrations and
eventually gout [28–30]. Theoretically, the ‘overproducers’
in the current concept, those with increased urinary uric
acid excretion, may include next to the genuine ‘uric acid
overproducers’ also ‘underexcretors of uric acid via the
intestine (extra-renal elimination)’ [28]. Unfortunately, it is
not feasible to determine uric acid excretion via the
intestine since it is degraded by uricase activity of the
intestinal microbiota, leading to an almost complete lack
of uric acid in the feces [31]. However, by excluding patients
on uric acid lowering therapy, we have attempted to
exclude those with gout and therefore possibly with
decreased renal or extra-renal excretion.
In addition, oxidation of hypoxanthine to xanthine does
not have to be equivalent to the oxidation of xanthine to
uric acid. Several feedback mechanisms can control the
supply of xanthine and thereby the corresponding uric acid
production [32]. For example, an increased urinary
excretion of xanthine [33] or degradation of xanthine
to xanthosine monophosphate by certain hypoxanthine–
guanine phosphoribosyltransferase [34] decreases the xan-
thine concentration. If this is the case, increased oxidation
of hypoxanthine to xanthine and the associated harmful
accumulation of ROS will not lead to an increased uric acid
production. In the future a systematic approach, integrating
the supply of hypoxanthine and xanthine and the involved
pathways might be a more accurate way to determine uric
acid production.
After adjustment for potential confounders (including
serum uric acid) the association between urinary uric acid
excretion and hypertension remained significant (Table 2,
model 3). Further adjustment for BMI (P¼ 0.80) or waist-to-
hip ratio (P¼ 0.45) attenuated the association. This might
be explained by the fact that adiposity increases xanthine
oxidoreductase activity in mice, thus leading to overpro-
duction of uric acid [26]. Adjustment for BMI or waist-to-hip
ratio (measure for abdominal visceral fat), might, therefore,
lead to overadjustment. Further research is required to
examine the influence of adiposity and visceral fat on uric
acid production and its association with hypertension. The
associations of serum uric acid with blood and hyperten-
sion were not attenuated after including BMI or waist-to-hip
ratio in the fully adjusted model. This is in line with the idea
that serum uric acid concentration does not reflect uric acid
production, as an increased uric acid production is com-
pensated by increased excretion to maintain serum uric
acid within the normal range.
In the present study, serum uric acid and urinary uric
acid excretion were associated with MAP but not with PP.
MAP is the steady component of BP reflecting vascular
resistance, which can be increased by inhibiting the vaso-
dilator nitric oxide. As previously described, several plaus-
ible mechanisms have been shown to link uric acid with a
decrease in the bioavailability of nitric oxide. PP, the
pulsatile component of BP, increases as a consequence
of prolonged exposure to increased vascular resistance and
elevated BP. This results in remodeling of the vascular
extracellular matrix [35,36], stiffening of the arteries and
ultimately a loss in vascular compliance. Thus far, no prior
studies investigated the association between uric acid and
PP in depth [37–42]. Previous studies, investigated the
association between uric acid and arterial stiffness. In line
with the current results, a study conducted in a subset of
The Maastricht Study population (n¼ 614), showed no
association of serum uric acid with stiffness of the aorta,
or the carotid or femoral artery [43]. Nonetheless, conclus-
ive evidence cannot be provided as the literature shows
disparate results [44–48]. We, therefore, emphasize the
need for further studies addressing the role of uric acid
on PP and arterial stiffness. In particular longitudinal stud-
ies, including middle-aged individuals, as uric acid may
lead to early changes in arterial stiffness and subsequently
to elevated PP, but may have less influence once vascular
damage is permanent [49].
The use of 24-h ambulatory BP measurements and the
adjustment for a large number of carefully measured poten-
tial confounders are major strengths of our study. Our study
also has some limitations which should be considered. We
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would like to emphasize the need for further research
validating urinary uric acid excretion as a proxy for uric
acid production. Furthermore, we proposed that accumu-
lation of ROS is a potential underlying mechanism linking
increased uric acid production with elevated BP, but from
the present study no conclusion can be drawn concerning
the actual mechanism. Owing to the cross-sectional nature
of this study, causal relationships could not be determined.
In addition, because of missing data, we had to exclude
almost 900 participants. Although we assumed the random
nature of these missing because most values were missing
because of logistic factors (e.g. the temporary unavailability
of ambulatory BP monitors), the excluded individuals had a
higher prevalence of (pre)diabetes and hypertension
(Table 1). Furthermore, serum uric acid and 24-h urinary
uric acid excretion was only determined once. As uric acid
concentrations can vary between days, multiple measures
would have been more accurate. Finally, our study popu-
lation consisted of relatively more individuals with T2DM
between 40–75 years of age; therefore, the results might not
be representative for the general population.
In conclusion, we found evidence for associations
between serum uric acid and urinary uric acid excretion
with ambulatory MAP and hypertension. By studying uri-
nary uric acid excretion, we aimed to investigate whether
an increased uric acid production was, independent of
serum uric acid, associated with BP. Finding significant
associations supports our hypothesis, highlighting the need
for further investigation on increased uric acid production
and its effect on urinary uric acid excretion and BP.
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Reviewers’ Summary Evaluations
Referee 1
In a relatively large sample size, the study showed that
serum concentration and urinary excretion of uric acid were
independently associated with hypertension and ambulat-
ory blood pressure. Twenty-four-hour urinary excretion of
uric acid can be considered as a proxy for uric acid
production. This study therefore raised a very good hypoth-
esis that should be tested in future prospective studies on
the underlying mechanisms for the possible role of uric acid
production in the pathogenesis of hypertension.
Referee 2
This is another nonpopulation-based cross-sectional study
about a possible association between serum uric acid and
arterial blood pressure levels (or diagnosis of hyperten-
sion). Here, urinary uric acid was used in multivariate
model. The results are that, as expected, the two items
are associated. Of course, the results cannot be extended
tout court to any subjects, because the records shown are
selected. Nevertheless, there is a certain interest in con-
firming a concept when two important risk factors or
indicators such as serum uric acid and hypertension 
and their possible interaction are investigated.
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